Anvisa's new rules to expedite the importation of cannabidiol medicines come into force
On April 22, 2015 Anvisa (National Sanitary Surveillance Agency) approved a new resolution that creates rules for the importation of five drugs based in cannabidiol for Brazil. The decision was voted by the Agency's Collegiate Board and published in the Official Gazette of the Union on May 8, scheduled to come into force only in two months. With them, it will be easier for patients to claim this importation and to enter the process.
The regulation serves as a complement to the actions already taken by Anvisa in order for patients to have access to the product. To do so, the patient must register with the Agency, using a document similar to the ones already used, which include the medical prescription. This register will be updated annually, using only the prescription and a doctor's report that indicates the evolution of the patient.
Five drug brands will be covered by these new standards, which correspond to 95% of current imports. In addition, patient associations can do this through import, which can reduce transportation and procurement costs.
Migraine is defined as throbbing, periodic headache that begins in childhood, adolescence or early adulthood and continues into subsequent years. But it goes far beyond the headache itself, having a group of symptoms such as: Nausea Aversion to clarity Hypersensitivity to noises and odors Dizziness Mood alteration Concentration and memory disorders Pressure changes Diarrhea.
Known as BDS (Deep Brain Stimulation), this treatment for Parkinson's drew attention on the internet following the release of a video of an elderly man from Louisiana in the United States. You received the electrodes, and as soon as the system was turned on by doctors, your body stopped shaking in a matter of moments.